bluebird bio (NASDAQ:BLUE – Free Report) had its price target reduced by Barclays from $4.00 to $2.00 in a research note released on Friday,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock. BLUE has been the subject of several other research reports. Bank of America downgraded shares of bluebird bio from […]